» Articles » PMID: 8697299

Insulin-secreting Cell Lines: Classification, Characteristics and Potential Applications

Overview
Journal Diabetes Metab
Specialty Endocrinology
Date 1996 Feb 1
PMID 8697299
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The use of primary beta-cells in biochemical and molecular research is limited by the availability of pancreatic endocrine tissue. Numerous investigators have attempted to establish an insulin-secreting cell line that retains normal regulation of insulin secretion. Different approaches have been used, including induction of pancreatic tumors by irradiation or viral infection, immortalization of beta-cells in vitro, and development of transgenic mice with targeted expression of a recombinant oncogene in the beta-cell. Few of these attempts have proven successful, because cell differentiation and proliferation capacities are mutually exclusive. The most widely used insulin-secreting cell lines are RIN, HIT, beta TC, MIN6 and INS-1 cells. These cells contain mainly insulin and small amounts of glucagon and somatostatin. RIN cells, except for the subclone RIN-38, are not glucose-responsive. HIT cells and beta TC cells secrete insulin in response to glucose, but their dose-response curve is markedly shifted to the left MIN6, INS-1 and a newly available subclone of beta TC cells (beta TC-6 F7) are reported to retain normal regulation of glucose-induced insulin secretion. Although the behaviour of none of these cell lines perfectly mimics primary beta-cell physiology, they are extremely valuable tools for the study of molecular events underlying beta-cell function and dysfunction. In addition, insulin-secreting cell lines represent a potential source of transplantable tissue to overcome the limited availability of primary islets for this procedure.

Citing Articles

High-Yield Generation of Glucose-Responsive Pseudoislets From Murine Insulinoma Cells for Studies and Longitudinal Monitoring of Graft Survival .

Gonzalez G, Li C, Pasolini I, Pete S, Verheyen C, Vignolo S Cell Transplant. 2025; 34:9636897251315123.

PMID: 39881520 PMC: 11780636. DOI: 10.1177/09636897251315123.


Structural insights into i-motif DNA structures in sequences from the insulin-linked polymorphic region.

Guneri D, Alexandrou E, El Omari K, Dvorakova Z, Chikhale R, Pike D Nat Commun. 2024; 15(1):7119.

PMID: 39164244 PMC: 11336075. DOI: 10.1038/s41467-024-50553-0.


Molecular mechanism of HNF-1A-mediated HNF4A gene regulation and promoter-driven HNF4A-MODY diabetes.

Kind L, Molnes J, Tjora E, Raasakka A, Myllykoski M, Colclough K JCI Insight. 2024; 9(11).

PMID: 38855865 PMC: 11382887. DOI: 10.1172/jci.insight.175278.


Structural properties of the HNF-1A transactivation domain.

Kind L, Driver M, Raasakka A, Onck P, Njolstad P, Arnesen T Front Mol Biosci. 2023; 10:1249939.

PMID: 37908230 PMC: 10613711. DOI: 10.3389/fmolb.2023.1249939.


Models in Pancreatic Neuroendocrine Neoplasms: Current Perspectives and Future Directions.

Forsythe S, Pu T, Andrews S, Madigan J, Sadowski S Cancers (Basel). 2023; 15(15).

PMID: 37568572 PMC: 10416968. DOI: 10.3390/cancers15153756.